Skip to main content
SpringerLink
Log in

Selecting the Optimal Oral Antihistamine for Patients with Allergic Rhinitis

  • Therapy In Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Allergic rhinitis (AR) is now recognised as a global health problem that affects 10–30% of adults and up to 40% of children. Each year, millions of patients seek treatment from their healthcare provider. However, the prevalence of AR maybe significantly underestimated because of misdiagnosis, under diagnosis and failure of patients to seek medical attention. In addition to the classical symptoms such as sneezing, nasal pruritus, congestion and rhinorrhoea, it is now recognised that AR has a significant impact on quality of life (QOL). This condition can lead to sleep disturbance as a result of nasal congestion, which leads to significant impairment in daily activities such as work and school. Traditionally, AR has been subdivided into seasonal AR (SAR) or perennial AR (PAR). SAR symptoms usually appear during a specific season in which aeroallergens are present in the outdoor air such as tree and grass pollen in the spring and summer and weed pollens in the autumn (fall); and PAR symptoms are present year-round and are triggered by dust mite, animal dander, indoor molds and cockroaches. Oral histamine H1-receptor antagonists (H1 antihistamines) are one of the most commonly prescribed medications for the treatment of AR. There are several oral H1 antihistamines available and it is important to know the pharmacology, such as administration interval, onset of action, metabolism and conditions that require administration adjustments. When prescribing oral H1 antihistamines, the healthcare provider must take into account the clinical efficacy and weigh this against the risk of adverse effects from the agent. In addition to the clinical efficacy, potential for improvement in QOL with a particular treatment should also be considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998 Nov; 81 (5): 478–518

    Article  PubMed  CAS  Google Scholar 

  2. Gandhi RK, Blaiss MS. Current concepts and therapeutic strategies for allergic rhinitis. Otorinolaringol 2005; 55 (3): 187–201

    Google Scholar 

  3. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001 Jul; 108 (1): S2–8

    Article  PubMed  CAS  Google Scholar 

  4. Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006 Jan; 117 (1): 158–62

    Article  PubMed  Google Scholar 

  5. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 Nov; 108 Suppl. 5: S147–334

    Article  PubMed  CAS  Google Scholar 

  6. Leynaert B, Neukirch C, Laird R, et al. Quality of life in allergic rhinitis and asthma: a population-based study of young adults. Am J Respir Crit Care Med 2000 Oct; 162 (4): 1391–6

    PubMed  CAS  Google Scholar 

  7. Craig TJ, McCann JL, Gurevich F, et al. The correlation between allergic rhinitis and sleep disturbance. J Allergy Clin Immunol 2004 Nov; 114 (5): S139–45

    Article  PubMed  Google Scholar 

  8. Huse DM, Hartz SE, Russell MW, et al. Allergic rhinitis may worsen asthma symptoms in children: the international asthma outcomes registry [abstract]. Am J Respir Crit Care Med 1996; 153: A860

    Google Scholar 

  9. Corren J, Adinoff AD, Irvin CG. Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol 1992; 89: 611–8

    Article  PubMed  CAS  Google Scholar 

  10. Corren J. Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol 1997; 99: S781–6

    Article  PubMed  CAS  Google Scholar 

  11. Blaiss M. Current concepts and therapeutic strategies for allergic rhinitis in school-age children. Clin Ther 2004; 26 (11): 1876–89

    Article  PubMed  Google Scholar 

  12. Naclerio RM. Allergic rhinitis. N Engl J Med 1991 Sep; 325 (12): 860–9

    Article  PubMed  CAS  Google Scholar 

  13. Meltzer EO. Evaluation of the optimal oral antihistamine for patients with allergic rhinitis. Mayo Clin Proc 2005 Sep; 80 (9): 1170–6

    Article  PubMed  CAS  Google Scholar 

  14. Naclerio RM, Proud D, Togias AG, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985 Jul; 313 (2): 65–70

    Article  PubMed  CAS  Google Scholar 

  15. Bascom R, Pipkorn U, Lichtenstein LM, et al. The influx of inflammatory cells into nasal washings during the late response to antigen challenge: effect of systemic steroid pretreatment. Am Rev Respir Dis 1988; 138: 406–12

    PubMed  CAS  Google Scholar 

  16. Ash ASF, Schild HO. Receptors mediating some actions of histamine. Br J Pharmacol 1966; 27: 427–39

    CAS  Google Scholar 

  17. Simons FER, Simons KJ. The pharmacology and use of H1-receptor-antagonist drags. N Engl J Med 1994; 330: 1663–70

    Article  PubMed  CAS  Google Scholar 

  18. Anthes J, Eckel S, Richard C, et al. Characterization of [3H] desloratadine at the human H1 receptor [abstract no. 526]. J Allergy Clin Immunol 2001; 107 Suppl. 2: 160

    Article  Google Scholar 

  19. Anthes JC, Gilchrest H, Richard C, et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor. Eur J Pharmacol 2002; 449: 229–37

    Article  PubMed  CAS  Google Scholar 

  20. Snyder SH, Snowman AM. Receptor effects of cetirizine. Ann Allergy 1987; 59 (6 Pt 2): 4–8

    PubMed  CAS  Google Scholar 

  21. Weiland K, Ter Laak AM, Smit MJ, et al. Mutational analysis of the antagonist-binding site of the histamine H1 receptor. J Biol Chem 1999; 274: 29994–30000

    Article  Google Scholar 

  22. Bakker RA, Schoonus SB, Smit MJ, et al. Histamine H1-receptor activation of nuclear factor-kappa B: roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol 2001; 60: 1133–42

    PubMed  CAS  Google Scholar 

  23. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32: 489–98

    Article  PubMed  CAS  Google Scholar 

  24. Rimmer SJ, Church MK. The pharmacology and mechanisms of action of histamine H1-antagonists. Clin Exp Allergy 1990 Aug; 20 Suppl. 2: 3–17

    Article  PubMed  Google Scholar 

  25. Naclerio RM. The effect of antihistamines on the immediate allergic response: a comparative review. Otolaryngol Head Neck Surg 1993 Jun; 108 (6): 723–30

    PubMed  CAS  Google Scholar 

  26. Ciprandi G, Passalacqua G, Canonica GW. Effects of H1 antihistamines on adhesion molecules: a possible rationale for long-term treatment. Clin Exp Allergy 1999; 29 Suppl. 3: 49–53

    PubMed  CAS  Google Scholar 

  27. Schroeder JT, Schleimer RP, Lichtenstein LM, et al. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001; 31: 1369–77

    Article  PubMed  CAS  Google Scholar 

  28. Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol 2000 Jun; 105 (6): S622–7

    Article  PubMed  CAS  Google Scholar 

  29. van Cauwenberge P, Bachert C, Passalacqua G, et al. European Academy of Allergology and Clinical Immunology. Consensus statement on the treatment of allergic rhinitis. Allergy 2000; 55: 116–34

    Article  PubMed  Google Scholar 

  30. International Rhinitis Management Working Group. International Consensus Report on the diagnosis and management of rhinitis. Allergy 1994; 49 Suppl. 19: 1–34

    Google Scholar 

  31. Passalacqua G, Bousquet J, Bachert C, et al. The clinical safety of H1-receptor antagonists: an EAACI position paper. Allergy 1996 Oct; 51 (10): 666–75

    PubMed  CAS  Google Scholar 

  32. Simons FER, Simons KJ. Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 1999; 36: 329–52

    Article  PubMed  CAS  Google Scholar 

  33. Baltes E, Coupez R, Giezek H, et al. Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. Fundam Clin Pharmacol 2001; 15: 269–77

    Article  PubMed  CAS  Google Scholar 

  34. Simons FER, Simons KJ. Peripheral H1-blockade effect of fexofenadine. Ann Allergy Asthma Immunol 1997; 79: 530–2

    Article  PubMed  CAS  Google Scholar 

  35. Simons FER. Advances in H1-antihistamines. N Engl J Med 2004 Nov; 351 (21): 2203–17

    Article  PubMed  CAS  Google Scholar 

  36. Hindmarch I, Johnson S, Meadows R, et al. The acute and subchronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. Curr Med Res Opin 2001; 17: 241–55

    PubMed  CAS  Google Scholar 

  37. van Steekelenburg J, Clement PAR, Beel MHL. Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests. Allergy 2002 Apr; 57: 346–50

    Article  PubMed  Google Scholar 

  38. Geha RS, Meltzer EO. Desloratadine: a new nonsedating, oral antihistamine. J Allergy Clin Immunol 2001 Apr; 107: 751–62

    Article  PubMed  CAS  Google Scholar 

  39. Simons FER, Silver NA, Gu X, et al. Skin concentrations of H1-receptor antagonists. J Allergy Clin Immunol 2001; 107: 526–30

    Article  PubMed  CAS  Google Scholar 

  40. Passalacqua G, Canonica GW. A review of evidence from comparative studies of levocetirizine and desloratadine for symptoms of allergic rhinitis. Clin Ther 2005 Jul; 27 (7): 979–92

    Article  PubMed  CAS  Google Scholar 

  41. Du Buske LM. Clinical comparison of histamine H1-receptor antagonist drags. J Allergy Clin Immunol 1996 Dec; 98 (6 Pt 3): S307–18

    Article  PubMed  Google Scholar 

  42. Golightly LK, Greos LS. Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs 2005; 65 (3): 341–84

    Article  PubMed  CAS  Google Scholar 

  43. Blaiss MS. Quality of life in allergic rhinitis. Ann Allergy Asthma Immunol 1999; 83: 449–54

    Article  PubMed  CAS  Google Scholar 

  44. Day JH, Briscoe MP, Rafeiro E, et al. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Units (EEU). Int J Clin Pract 2004; 59: 109–18

    Article  Google Scholar 

  45. Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 1996; 97: 617–6

    Article  PubMed  CAS  Google Scholar 

  46. Ciprandi G, Passalacqua G, Mincarini M, et al. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 507–11

    Article  PubMed  CAS  Google Scholar 

  47. Ciprandi G, Tosca M, Ricca V, et al. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. Clin Exp Allergy 1997; 27: 1160–6

    Article  PubMed  CAS  Google Scholar 

  48. Pearlman DS, Lumry WR, Winder JA, et al. Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: a randomized, double-blind, placebo-controlled study. Clin Pediatr 1997; 36: 209–15

    Article  CAS  Google Scholar 

  49. Sabbah A, Daele J, Wade AG, et al. Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 1999; 83: 319–25

    Article  PubMed  CAS  Google Scholar 

  50. Murray JJ, Nathan RA, Bronsky EA, et al. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc 2002; 23: 391–8

    PubMed  CAS  Google Scholar 

  51. Noonan MJ, Raphael GD, Nayak A, et al. The health-related quality of life effects of once-daily cetirizine HCl in patients with seasonal allergic rhinitis: a randomized double-blind, placebo-controlled trial. Clin Exp Allergy 2003; 33: 351–8

    Article  PubMed  CAS  Google Scholar 

  52. Horak F, Stiibner UP, Zieglmayer R, et al. Controlled comparison of the efficacy and safety of cetirizine 10mg od and fexofenadine 120mg od in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001; 125: 73–9

    Article  PubMed  CAS  Google Scholar 

  53. Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 927–33

    Article  PubMed  CAS  Google Scholar 

  54. Hampel F, Ratner P, Mansfield L, et al. Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91: 354–61

    Article  PubMed  CAS  Google Scholar 

  55. Day JH, Briscoe MP, Clark RH, et al. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Asthma Allergy Immunol 1997; 79: 163–72

    Article  CAS  Google Scholar 

  56. Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol 1998; 101: 638–45

    Article  PubMed  CAS  Google Scholar 

  57. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001; 56: 1077–80

    Article  PubMed  CAS  Google Scholar 

  58. Salmun LM, Lorber R, Danzig M, et al. Efficacy and safety of desloratadine in seasonal allergic rhinitis [abstract no. 1123]. J Allergy Clin Immunol 2000; 104 Suppl. 1: 384–5

    Article  Google Scholar 

  59. Heithoff K, Meltzer EO, Mellars L, et al. Desloratadine improves quality of life in patients with seasonal allergic rhinitis [abstract no. 1121]. J Allergy Clin Immunol 2000; 104 Suppl. 1: 383–4

    Article  Google Scholar 

  60. Meltzer EO, Prenner BM, Nayak A. Efficacy and tolerability of once-daily 5mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy seasons. Clin Drug Invest 2001; 21: 25–32

    Article  CAS  Google Scholar 

  61. Berger WE, Schenkel EJ, Mansfield LE, et al. Safety and efficacy of desloratadine 5mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002; 89: 485–91

    Article  PubMed  CAS  Google Scholar 

  62. Salmun LM, Lorber R. 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis. BMC Fam Pract 2002; 3: 14–20

    Article  PubMed  Google Scholar 

  63. Wilson AM, Haggart K, Sims EJ, et al. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002; 32: 1504–9

    Article  PubMed  CAS  Google Scholar 

  64. Day JH, Briscoe MP, Welsh A, et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol 1997; 79: 533–40

    Article  PubMed  CAS  Google Scholar 

  65. Wahn U, Meltzer EO, Finn AF, et al. Fexofenadine is efficacious and safe in children (aged 6–11 years) with seasonal allergic rhinitis. J Allergy Clin Immunol 2003; 111: 763–9

    Article  PubMed  CAS  Google Scholar 

  66. Sussman GL, Mason J, Compton D, et al. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 100–6

    Article  PubMed  CAS  Google Scholar 

  67. Casale TB, Andrade C, Qu R. Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergy rhinitis. Allergy Asthma Proc 1999; 20: 193–8

    Article  PubMed  CAS  Google Scholar 

  68. Bronsky EA, Falliers CJ, Kaiser HB, et al. Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc 1998; 19: 135–41

    Article  PubMed  CAS  Google Scholar 

  69. Meltzer EO, Casale TB, Nathan RA, et al. Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1999; 83: 311–7

    Article  PubMed  CAS  Google Scholar 

  70. Bernstein DI, Schoenwetter WF, Nathan RA, et al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 443–8

    Article  PubMed  CAS  Google Scholar 

  71. van Cauwenberge P, Juniper EF, Meltzer EO, et al. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120mg, loratadine 10mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000; 30: 891–9

    Article  PubMed  Google Scholar 

  72. Mösges R, van Cauwenberg P, Purello-D’Ambrosio F, et al. Fexofenadine and loratadine exhibit rapid relief, but only fexofenadine maintains efficacy over a 2-week period [abstract no. 1005]. Allergy 2000; 55 Suppl. 63: 281

    Google Scholar 

  73. Ricard N, Kind P, Christian S, et al. Link between preferences and treatment outcomes in seasonal allergic rhinitis: an empiric investigation. Clin Ther 1999; 20: 268–77

    Article  Google Scholar 

  74. Serra HA, Alves O, Rizzo LFL, et al. Loratadinepseudoephedrine in children with allergic rhinitis, a controlled double-blind trial. Br J Clin Pharmacol 1998; 45: 147–50

    Article  PubMed  CAS  Google Scholar 

  75. Druce HM, Thoden WR, Mure P, et al. Brompheniramine, loratadine, and placebo in allergic rhinitis: a placebo-controlled comparative trial. J Clin Pharmacol 1998; 38: 382–9

    PubMed  CAS  Google Scholar 

  76. Pagliara A, Testa B, Carrupt P-A, et al. Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist. J Med Chem 1998; 41: 853–63

    Article  PubMed  CAS  Google Scholar 

  77. Best CH, Dale HH, Dudley HW, et al. The nature of the vasodilator constituents of certain tissue extracts. J Physiol 1927; 62: 397–417

    PubMed  CAS  Google Scholar 

  78. Zyrtec® (cetirizine hydrochloride) tablets and syrup: package insert. New York: Pfizer Inc., 2002

    Google Scholar 

  79. Mohler SR, Nicholson A, Harvey RP, et al. The use of antihistamines in safety-critical jobs: a meeting report. Curr Med Res Opin 2002; 18: 332–7

    Article  PubMed  CAS  Google Scholar 

  80. Lai DS, Lue KH, Hsieh JC, et al. The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89: 589–98

    Article  PubMed  CAS  Google Scholar 

  81. Burtin B, Duchateau J, Pignat JC, et al. Further improvement of quality of life by cetirizine in perennial allergic rhinitis as a function of treatment duration. Invest Allergol Clin Immunol 2000; 10: 66–70

    CAS  Google Scholar 

  82. Ciprandi G, Tosca MA, Cosentino C, et al. Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. J Allergy Clin Immunol 2003 Oct; 112 (4 Suppl.): S78–82

    Article  PubMed  CAS  Google Scholar 

  83. Kay GG, Berman B, Mockoviak SH, et al. Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance. Arch Intern Med 1997; 157: 2350–6

    Article  PubMed  CAS  Google Scholar 

  84. Hindmarch I, Shamsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy 1999; 29 Suppl. 3: 133–42

    Article  PubMed  CAS  Google Scholar 

  85. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005; 65 (2): 215–28

    Article  PubMed  CAS  Google Scholar 

  86. Paolieri F, Battifora M, Riccio A, et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol 1998; 81: 601–7

    Article  PubMed  CAS  Google Scholar 

  87. Allegra® (fexofenadine hydrochloride) capsules and tablets: package insert. Kansas City (MO): Aventis Pharmaceuticals Inc., 2003

    Google Scholar 

  88. Clarinex® (desloratadine) tablets: package insert. Kenilworth (NJ): Schering Corporation, 2002

    Google Scholar 

  89. Bower EA, Moore JL, Moss M, et al. The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel. Aviat Space Environ Med 2003; 74: 145–52

    PubMed  CAS  Google Scholar 

  90. Thomson L, Blaylock MG, Sexton DW, et al. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy 2002; 32: 1187

    Article  PubMed  CAS  Google Scholar 

  91. Simons FER, Prenner BM, Finn A. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2003; 111: 617–22

    Article  PubMed  CAS  Google Scholar 

  92. Xyzal® (levocetirizine) tablets: package insert. Brussels: UCB Pharma Ltd, 2003

    Google Scholar 

  93. de Blic J, Wahn U, Billard E. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr Allergy Immunol 2005 May; 16 (3): 267–75

    Article  PubMed  Google Scholar 

  94. Lee DK, Gardiner M, Haggart K, et al. Comaprative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin Exp Allergy 2004; 34: 650–3

    Article  PubMed  CAS  Google Scholar 

  95. Taglialatela M, Timmerman H, Annunziato L. Cardiotoxic potential and CNS effects of first-generation antihistamines. Trends Pharmacol Sci 2000; 21: 52–6

    Article  PubMed  CAS  Google Scholar 

  96. Bockholdt B, Klug E, Schneider V. Suicide through doxylamine poisoning. Forensic Sci Int 2001; 119: 138–40

    Article  PubMed  CAS  Google Scholar 

  97. Baker AM, Johnson DG, Levisky JA, et al. Fatal diphenhydramine intoxication in infants. J Forensic Sci 2003; 48: 425–8

    PubMed  Google Scholar 

  98. Claritin® (loratadine) tablets, syrup, and rapidly-disintegrating tablets: package insert. Kenilworth (NJ): Schering Corporation, 2000

    Google Scholar 

  99. Timmerman H. Factors involved in the absence of sedative effects by second-generation antihistamines. Allergy 2000; 55 Suppl. 60: 5–10

    Article  PubMed  Google Scholar 

  100. Simons FER, Fraser TG, Maher J, et al. Central nervous system effects of H1-receptor antagonists in the elderly. Ann Allergy Asthma Immunol 1999; 82: 157–60

    Article  PubMed  CAS  Google Scholar 

  101. Simons FER, Fraser TG, Reggin JD, et al. Comparison of the central nervous system effects produced by six H1-receptor antagonists. Clin Exp Allergy 1996; 26: 1092–7

    Article  PubMed  CAS  Google Scholar 

  102. Scharf MB, Kay G, Rikken G, et al. Desloratadine has no effect on wakefulness or psychomotor performance [abstract no. 1001]. Allergy 2000; 55 Suppl. 63: 280

    Google Scholar 

  103. Tashiro M, Sakurada Y, Iwabuchi K, et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol 2004; 44: 890–900

    Article  PubMed  CAS  Google Scholar 

  104. Ramaekers JG, Uiterwijk MMC, O’Hanlon JF. Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Eur J Clin Pharmacol 1992; 42: 363–9

    PubMed  CAS  Google Scholar 

  105. Vermeeren A, Ramaekers JG, O’Hanlon JF. Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females. J Psychopharmacol 2002; 16: 57–64

    Article  PubMed  CAS  Google Scholar 

  106. Gengo FM, Gabos C, Mechtler L. Quantitative effects of cetirizine and diphenhydramine on mental performance measured using an automobile driving simulator. Ann Allergy 1990; 64: 520–6

    PubMed  CAS  Google Scholar 

  107. Gengo FM, Gabos C. Antihistamines, drowsiness, and psychomotor impairment: central nervous system effect of cetirizine. Ann Allergy 1987; 59 (6 Pt 2): 53–7

    PubMed  CAS  Google Scholar 

  108. Walsh JK, Muehlbach MJ, Schweitzer PK. Simulated assembly line performance following ingestion of cetirizine or hydroxyzine. Ann Allergy 1992; 69: 195–200

    PubMed  CAS  Google Scholar 

  109. Vuurman EFPM, Rikken GH, Muntjewerff ND, et al. Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur J Clin Pharmacol 2004; 60: 307–13

    Article  PubMed  CAS  Google Scholar 

  110. Hindmarch I, Shamsi Z, Stanley N, et al. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol 1999; 48: 200–6

    Article  PubMed  CAS  Google Scholar 

  111. Verster JC, Volkerts ER, van Oosterwijck AW, et al. Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. J Allergy Clin Immunol 2003 Mar; 111 (3): 623–7

    Article  PubMed  CAS  Google Scholar 

  112. Taglialatela M, Timmerman H, Annunziato L. Cardiotoxic potential and CNS effects of first-generation antihistamines. Trends Pharmacol Sci 2000; 21: 52–6

    Article  PubMed  CAS  Google Scholar 

  113. Milne RW, Larson LA, Jorgensen KL, et al. Hepatic disposition of fexofenadine: influence of the inhibitors erythromycin and dibromosulphothalein. Pharm Res 2000; 17: 1511–5

    Article  PubMed  CAS  Google Scholar 

  114. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361–98

    Article  PubMed  CAS  Google Scholar 

  115. Tian R, Koyabu N, Takanaga H, et al. Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm Res 2002; 19: 802–9

    Article  PubMed  CAS  Google Scholar 

  116. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002; 71: 11–20

    Article  PubMed  CAS  Google Scholar 

  117. Hamman MA, Bruce MA, Hachner-Daniels BD, et al. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001; 69: 114–21

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Dr Blaiss has acted as a consultant and has received honoraria from Alcon, Alliant, Altana, Astra Zeneca, GlaxoSmithKline, Inspire, King, Merck, sanofi-aventis, Schering Plough and Teva, and has stock or options in Schering Plough. Dr Lehman has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Pediatrics, Division of Clinical Allergy and Immunology, University of Tennessee Health Science Center, Memphis, Tennessee, USA

    Jeffrey M. Lehman &  Michael S. Blaiss

Authors
  1. Jeffrey M. Lehman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael S. Blaiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael S. Blaiss.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lehman, J.M., Blaiss, M.S. Selecting the Optimal Oral Antihistamine for Patients with Allergic Rhinitis. Drugs 66, 2309–2319 (2006). https://doi.org/10.2165/00003495-200666180-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666180-00004

Keywords

Search

Navigation